Rapid and random-start endometrial preparation before outpatient hysteroscopic polypectomy in patients of perimenopausal age.

IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Climacteric Pub Date : 2024-09-27 DOI:10.1080/13697137.2024.2404574
Andrea Etrusco, Antonio D'Amato, Vittorio Agrifoglio, Vito Chiantera, Giuseppe Russo, Tullio Golia D'Augè, Marco Monti, Gaetano Riemma, Antonio Simone Laganà, Andrea Giannini
{"title":"Rapid and random-start endometrial preparation before outpatient hysteroscopic polypectomy in patients of perimenopausal age.","authors":"Andrea Etrusco, Antonio D'Amato, Vittorio Agrifoglio, Vito Chiantera, Giuseppe Russo, Tullio Golia D'Augè, Marco Monti, Gaetano Riemma, Antonio Simone Laganà, Andrea Giannini","doi":"10.1080/13697137.2024.2404574","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the efficacy of randomly started oral dienogest/ethinylestradiol (DNG/EE) for swift endometrial preparation prior to outpatient hysteroscopic polypectomy in perimenopausal women.</p><p><strong>Method: </strong>A multicenter, prospective, randomized controlled trial was conducted in university hospitals. Eighty perimenopausal women scheduled for outpatient hysteroscopic polypectomy between January 2023 and March 2024 were randomly assigned to either intervention (<i>n</i> = 40) or control (<i>n</i> = 40) groups. Exclusion criteria included concomitant endometrial pathologies, recent therapy and adnexal diseases. The intervention group received oral DNG/EE 2 mg/0.03 mg/day started on any day of the menstrual cycle for 14 days. The control group underwent polypectomy between menstrual cycle days 8 and 11 without pharmacological treatment.</p><p><strong>Results: </strong>Pre-procedure (<i>p</i> < 0.001) and post-procedure (<i>p</i> < 0.001) endometrial thickness were significantly reduced in the intervention group, along with a higher incidence of hypotrophic/atrophic endometrial patterns (<i>p</i> < 0.001). Surgical parameters also differed significantly between groups.</p><p><strong>Conclusion: </strong>DNG/EE treatment offers rapid, cost-effective endometrial preparation, enhancing surgical outcomes and patient satisfaction during outpatient polypectomy.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT06316206.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-7"},"PeriodicalIF":2.9000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2024.2404574","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to assess the efficacy of randomly started oral dienogest/ethinylestradiol (DNG/EE) for swift endometrial preparation prior to outpatient hysteroscopic polypectomy in perimenopausal women.

Method: A multicenter, prospective, randomized controlled trial was conducted in university hospitals. Eighty perimenopausal women scheduled for outpatient hysteroscopic polypectomy between January 2023 and March 2024 were randomly assigned to either intervention (n = 40) or control (n = 40) groups. Exclusion criteria included concomitant endometrial pathologies, recent therapy and adnexal diseases. The intervention group received oral DNG/EE 2 mg/0.03 mg/day started on any day of the menstrual cycle for 14 days. The control group underwent polypectomy between menstrual cycle days 8 and 11 without pharmacological treatment.

Results: Pre-procedure (p < 0.001) and post-procedure (p < 0.001) endometrial thickness were significantly reduced in the intervention group, along with a higher incidence of hypotrophic/atrophic endometrial patterns (p < 0.001). Surgical parameters also differed significantly between groups.

Conclusion: DNG/EE treatment offers rapid, cost-effective endometrial preparation, enhancing surgical outcomes and patient satisfaction during outpatient polypectomy.

Trial registration: ClinicalTrials.gov NCT06316206.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
围绝经期患者在门诊宫腔镜息肉切除术前快速和随机启动子宫内膜准备。
研究目的本研究旨在评估围绝经期妇女在门诊宫腔镜息肉切除术前随机开始口服双烯雌酚/炔雌醇(DNG/EE)以迅速进行子宫内膜准备的疗效:在大学医院开展了一项多中心、前瞻性、随机对照试验。80名计划在2023年1月至2024年3月期间接受门诊宫腔镜息肉切除术的围绝经期妇女被随机分配到干预组(40人)或对照组(40人)。排除标准包括合并子宫内膜病变、近期接受过治疗和患有附件疾病。干预组在月经周期的任何一天开始口服 DNG/EE 2 毫克/0.03 毫克/天,持续 14 天。对照组在月经周期第 8 天和第 11 天之间接受息肉切除术,不进行药物治疗:手术前(P P P P 结论:DNG/EE治疗提供了快速、经济有效的子宫内膜准备,提高了门诊息肉切除术的手术效果和患者满意度:试验注册:ClinicalTrials.gov NCT06316206。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Climacteric
Climacteric 医学-妇产科学
CiteScore
1.70
自引率
7.10%
发文量
53
审稿时长
1 months
期刊介绍: Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.
期刊最新文献
Hyperandrogenism after menopause: diagnostic evaluation. Factors influencing seogeulpeum among middle-aged Korean women. Perimenopausal combined hormonal contraception: focus on sexual function. Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion. Hyaluronic acid and erbium laser for the treatment of genitourinary syndrome of menopause.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1